



HELPING THE PATIENT WITH PAIN No 6: Understanding the adverse effects of opioids

FURTHER READING

Journal articles

- Boyd KJ, Kelly M. Oral morphine as symptomatic treatment of dyspnoea in patients with advanced cancer. *Palliative Medicine*. 1997; 11(4): 277-81.
- Bruera E, Macmillan K, Pither J, MacDonald RN. Effects of morphine on the dyspnoea of terminal cancer patients. *J Pain & Symp Manag*, 1990; 5(6): 341-44.
- Chan JD et al. Narcotic and benzodiazepines use after withdrawal of life support: association with time of death? *Chest*. 2004; 126(1): 286-93.
- Estfan et al. *Palliative Medicine*. 2007, March.
- Good PD, Ravenscroft PJ, Cavenagh J. Effects of opioids and sedatives on survival in an Australian inpatient palliative care population. *Int Med J*. 2005; 35(9): 512-7
- Hanks GW, Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, Mercadante S, Meynadier J, Poulain P, Ripamonti C, Radbruch L, Casas JR, Sawe J, Twycross RG, Ventafridda V. Expert Working Group of the Research Network of the European Association for Palliative Care. Morphine and alternative opioids in cancer pain: the EAPC recommendations. *British Journal of Cancer*. 2001; 84(5): 587-93.
- Hu WY, Chiu TY, Cheng SY, Chen CY. Morphine for dyspnoea control in terminal cancer patients: is it appropriate in Taiwan? *J Pain & Symp Manag*. 2004; 28(4): 356-63.
- Kirvela M, Lindgren L, Seppala T, Olkkola KT. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. *Journal of Clinical Anesthesia*. 1996; 8(1):13-8.
- Lee MA, Leng ME, Tiernan EJ. Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. *Palliative Medicine*. 2001; 15(1):26-34.
- Mazoit JX, Sardouk P, Zetlaoui P *et al*. Pharmacokinetics of unchanged morphine in normal and cirrhotic patients. *Anaesthesia and Analgesia*, 1987; 66: 293-98.
- Mazzocato C, Buclin T, Rapin CH. The effects of morphine on dyspnoea and ventilatory function in elderly patients with advanced cancer: a randomized double-blind control trial. *Annals of Oncology*. 1999; 10(12): 1511-4.
- Morita T, Tsunoda J, Inoue S, Chihara S. Effects of high dose opioids and sedatives on survival in terminally ill cancer patients. *J Pain & Symp Manag*. 2001; 21(4): 282-9.
- Portenoy RK, Thaler HT, Inturrisi CE *et al* The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function. *Clinical Pharmacology and Therapeutics* 1992; 51: 422-431.
- Regnard C and Badger C. Opioids, sleep and the time of death. *Palliative Medicine*, 1987; 1(2): 107-110.
- Sarhill N, Walsh D, Nelson KA. Hydromorphone: pharmacology and clinical applications in cancer patients. *Supportive Care in Cancer*. 2001; 9(2): 84-96.
- Sykes N, Thorns A. Sedative use in the last week of life and the implications for end-of-life decision making. *Arch Int Med* 2003; 163(3): 341-4

Resource books and websites

A Guide to Symptom Relief in Palliative Care, 5th ed. Regnard C, Hockley J. Abingdon: Radcliffe Medical Press, 2004

Cancer Pain Relief and Palliative Care. Geneva : WHO, 1990.

Oral Morphine, Information for Patients, Families and Friends. Twycross R., Lack S.A. Beaconsfield Publishers. 1988.

Oxford Textbook of Palliative Medicine 3rd ed. Doyle D, Hanks G, Cherny NI, Calman K eds. Oxford : Oxford University Press, 2003.

PCF3- Palliative Care Formulary, 3rd ed. Twycross RG, Wilcock A. Oxford: Radcliffe Press, 2008. Also on www.palliativedrugs.com

Symptom Management in Advanced Cancer, 3rd edition. 2001. Twycross RG, Wilcock A. Abingdon: Radcliffe Medical Press.

Wall and Melzack's textbook of pain, 5th ed. Stephen B. McMahon and Martin Koltzenburg, eds. Edinburgh : Elsevier Churchill Livingstone, 2006..

CREDITS

This version written and edited by:

Claud Regnard, Consultant in Palliative Medicine, St. Oswald's Hospice, Newcastle City Hospitals NHS Trust and Northgate&Prudhoe NHS Trust